ROR1 and B-cell chronic lymphocytic leukemia: Zilovertamab (formerly cirmtuzumab and UC-961), a humanized monoclonal antibody, has demonstrated the ability to inhibit WNT5A/ROR1 signaling in leukemic cells and was in clinical trials for CLL [6].